Current ACC/AHA ischemic heart disease guideline set
The latest ACC/AHA guidance for ischemic heart disease management is organized by clinical syndrome: acute coronary syndromes (ACS), chronic coronary disease (CCD), and coronary artery revascularization. [1], [2], [3]
- Acute coronary syndromes: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. [1]
- Chronic coronary disease: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. [2]
- Coronary artery revascularization: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. [3]
Medication selection algorithm for chronic coronary disease
Management of CCD is built around guideline-directed medical therapy with stratification by symptom burden, ischemic risk, and secondary prevention status. [2]
Core cardiovascular prevention and disease-modifying therapy components in CCD include the following: [2]
- Antiplatelet therapy when oral anticoagulation is not indicated. [2]
- Oral anticoagulation when indicated by comorbid conditions (for example, atrial fibrillation) and avoidance of unnecessary combination therapy. [2]
- Lipid-lowering therapy with high-intensity statin strategies when feasible. [2]
- Additional nonstatin lipid-lowering therapy based on LDL-C or non–HDL-C thresholds and risk level. [2]
- Antianginal symptom therapy using agents selected to improve angina control. [2]
Lipid management goals for chronic coronary disease
For secondary prevention, LDL-C targets are intensity-based and risk-stratified in CCD care. [2], [4]
LDL-C targets reported in ACC/AHA materials for secondary prevention include: [4]
- LDL-C <70 mg/dL for high-risk patients. [4]
- LDL-C <55 mg/dL for patients at very high risk of ASCVD events. [4]
Escalation beyond statin therapy in CCD is described with add-on nonstatin therapy when LDL-C remains above threshold despite maximally tolerated statin and ezetimibe in very-high-risk patients. [2]
Antiplatelet and anticoagulation principles in chronic coronary disease
Antiplatelet and anticoagulation recommendations in CCD distinguish patients receiving oral anticoagulation from those who are not. [2]
Key structural CCD antithrombotic recommendations include: [2]
- Use of antiplatelet therapy strategies when oral anticoagulation is not indicated. [2]
- Selection and duration of dual antiplatelet therapy based on clinical scenario and procedural context. [2]
Revascularization decision framework in ischemic heart disease
Revascularization is recommended based on survival benefit potential, expected reduction in myocardial infarction risk, and the balance of procedural risk with coronary anatomy and patient comorbidity. [3]
Revascularization is generally considered in SIHD when coronary anatomy and risk predict a net benefit from revascularization rather than medical therapy alone. [3]
In SIHD patients with multivessel CAD who are appropriate candidates for either CABG or PCI, revascularization is described as reasonable to lower the risk of cardiovascular events including spontaneous MI, unplanned urgent revascularizations, or cardiac death. [3]
In patients with diabetes and multivessel CAD with involvement of the LAD and who are appropriate CABG candidates, CABG is recommended in preference to PCI to reduce mortality and repeat revascularizations. [3]
In patients with SIHD with normal left ventricular ejection fraction and 1- or 2-vessel CAD not involving the proximal LAD, coronary revascularization is described as not recommended to improve survival. [3]
Acute coronary syndromes medication framework (2025 ACS guideline)
The 2025 ACS guideline places dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor as a foundational strategy for ACS, with agent and duration informed by ischemic versus bleeding risk. [1], [5]
Evidence summarized in ACS guidance includes that prasugrel or ticagrelor reduces the rate of the composite endpoint of cardiovascular death, MI, or stroke by approximately 16% to 20% compared with clopidogrel in landmark trials. [1]
Targets and follow-up priorities across guidelines
Chronic coronary disease guideline follow-up emphasizes monitoring of symptoms, risk factor control, and adherence to secondary prevention therapy. [2]
ACS and CCD guidance both emphasize integrating pharmacotherapy with revascularization decisions when indicated and aligning treatment intensity with risk status. [1], [2], [3]